Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: mappingworld who wrote (3236)	2/2/2000 8:50:00 AM
From: JAMES BORECKI	Read Replies (4) \| Respond to of 14101

Rabecca just finished an interview on ROBTV. No Surprises which in one way is a little disappointing but on the other hand it confirms that this thread is getting as much information as there is to get. Pensaid: Started with a description of what Pensaid did: sight specific to localize medication and avoid side effects. Pointed out that 16,000 people die in US annually. "Die from treatment rather than the disease." No mention of fungal or AIDS research at any time. Submission: Difficult to predict. Was VERY careful not to suggest that the Canadian regulatory committee was in any way a difficult organization to work with. That it was a independent organization and that US approval didn't automatically mean approval in Canada. (was rather funny/sad seeing Rabecca walking on egg shells at this point.) All she would say was "Near term Canadian approval". UK approval was great because it now accelerates the process not only throughout the rest of Europe but also throughout the rest of the world because the UK testing standards are acknowledged internationally. $10,000,000: Is targeted for commercial launching of Pensaid. They want to retain manufacturing and distribution for a bigger share of the pie. $5 Billion market: They have intentionally kept a low profile. "We've always promoted what we've done rather than what we are going to do" Is this the year? Rabecca never answered this directly but brought out positives like being a fully integrated pharmaceutical and that a burn rate of $400K per month will give them enough money to get Pensaid to market. They are looking forward to a Nasdaq listing where all the big investors are. (I am very unsure that she said 400K, it seems a little high, but that's what I have in my notes so maybe someone else can confirm or deny) Personal observations. She came across very well. There was no sense of 'IF' but rather only of 'WHEN'. The interviewer must have followed the Dimethaid thread; he seemed to ask all the right questions in the right order. We've heard it all before and that's a credit to all of you. I hope this keeps the spirits up and on behalf of all DMX lurkers thanks to everyone for their efforts. JimB